It has been demonstrated that as a critical activated receptor on CD8+T cells, the expression of CD226 and the frequency of CD226+CD8+TILs are significantly and positively associated with the clinical benefit of ICB in certain human cancers (17, 32). The gene discussed is CD8A; the disease is cancer.